194 related articles for article (PubMed ID: 27775078)
21. Expression of CYLD, NF-kappaB and NF-kappaB-related factors in salivary gland tumors.
Fukuda M; Fukuda F; Horiuchi Y; Oku Y; Suzuki S; Kusama K; Sakashita H
In Vivo; 2006; 20(4):467-72. PubMed ID: 16900776
[TBL] [Abstract][Full Text] [Related]
22. The tumor suppressor CYLD regulates entry into mitosis.
Stegmeier F; Sowa ME; Nalepa G; Gygi SP; Harper JW; Elledge SJ
Proc Natl Acad Sci U S A; 2007 May; 104(21):8869-74. PubMed ID: 17495026
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA and transcription factor co-regulatory network analysis reveals miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia.
Ye H; Liu X; Lv M; Wu Y; Kuang S; Gong J; Yuan P; Zhong Z; Li Q; Jia H; Sun J; Chen Z; Guo AY
Nucleic Acids Res; 2012 Jul; 40(12):5201-14. PubMed ID: 22362744
[TBL] [Abstract][Full Text] [Related]
24. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options.
van Andel H; Kocemba KA; Spaargaren M; Pals ST
Leukemia; 2019 May; 33(5):1063-1075. PubMed ID: 30770859
[TBL] [Abstract][Full Text] [Related]
25. The tumor suppressor CYLD controls the function of murine regulatory T cells.
Reissig S; Hövelmeyer N; Weigmann B; Nikolaev A; Kalt B; Wunderlich TF; Hahn M; Neurath MF; Waisman A
J Immunol; 2012 Nov; 189(10):4770-6. PubMed ID: 23066153
[TBL] [Abstract][Full Text] [Related]
26. Deubiquitinating activity of CYLD is impaired by SUMOylation in neuroblastoma cells.
Kobayashi T; Masoumi KC; Massoumi R
Oncogene; 2015 Apr; 34(17):2251-60. PubMed ID: 24909169
[TBL] [Abstract][Full Text] [Related]
27. CYLD: a deubiquitination enzyme with multiple roles in cancer.
Massoumi R
Future Oncol; 2011 Feb; 7(2):285-97. PubMed ID: 21345146
[TBL] [Abstract][Full Text] [Related]
28. Thymocyte-specific truncation of the deubiquitinating domain of CYLD impairs positive selection in a NF-kappaB essential modulator-dependent manner.
Tsagaratou A; Trompouki E; Grammenoudi S; Kontoyiannis DL; Mosialos G
J Immunol; 2010 Aug; 185(4):2032-43. PubMed ID: 20644164
[TBL] [Abstract][Full Text] [Related]
29. KLHL21/CYLD signaling confers aggressiveness in bladder cancer through inactivating NF-κB signaling.
Yuan H; Wei S; Ren Z; Li F; Liu B; Liu R; Zhang X
Int Immunopharmacol; 2023 Jan; 114():109202. PubMed ID: 36538852
[TBL] [Abstract][Full Text] [Related]
30. Inactivation of deubiquitinase CYLD enhances therapeutic antibody production in Chinese hamster ovary cells.
Lu Y; Zhou Q; Han Q; Wu P; Zhang L; Zhu L; Weaver DT; Xu C; Zhang B
Appl Microbiol Biotechnol; 2018 Jul; 102(14):6081-6093. PubMed ID: 29766242
[TBL] [Abstract][Full Text] [Related]
31. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB.
Brummelkamp TR; Nijman SM; Dirac AM; Bernards R
Nature; 2003 Aug; 424(6950):797-801. PubMed ID: 12917690
[TBL] [Abstract][Full Text] [Related]
32. Over-expressing CYLD augments antitumor activity of TRAIL by inhibiting the NF-κB survival signaling in lung cancer cells.
Deng LL; Shao YX; Lv HF; Deng HB; Lv FZ
Neoplasma; 2012; 59(1):18-29. PubMed ID: 22017589
[TBL] [Abstract][Full Text] [Related]
33. PCDH10 inhibits cell proliferation of multiple myeloma via the negative regulation of the Wnt/β-catenin/BCL-9 signaling pathway.
Xu Y; Yang Z; Yuan H; Li Z; Li Y; Liu Q; Chen J
Oncol Rep; 2015 Aug; 34(2):747-54. PubMed ID: 26081897
[TBL] [Abstract][Full Text] [Related]
34. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling.
Massoumi R; Chmielarska K; Hennecke K; Pfeifer A; Fässler R
Cell; 2006 May; 125(4):665-77. PubMed ID: 16713561
[TBL] [Abstract][Full Text] [Related]
35. Tumor suppressor CYLD: negative regulation of NF-kappaB signaling and more.
Courtois G
Cell Mol Life Sci; 2008 Apr; 65(7-8):1123-32. PubMed ID: 18193168
[TBL] [Abstract][Full Text] [Related]
36. CYLD expression in dendritic cells involved in the immunoregulation of pulmonary adenocarcinoma via NF-κB pathway.
Yu Q; Lei Y; Huang Y; Zhang J; Chen Y; Chen K; Lin J; Sun S; Lin X
Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):137-142. PubMed ID: 31852310
[TBL] [Abstract][Full Text] [Related]
37. Anti-proliferative activity of CGK012 against multiple myeloma cells via Wnt/β-catenin signaling attenuation.
Choi PJ; O Y; Her JH; Yun E; Song GY; Oh S
Leuk Res; 2017 Sep; 60():103-108. PubMed ID: 28772205
[TBL] [Abstract][Full Text] [Related]
38. The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor.
Regamey A; Hohl D; Liu JW; Roger T; Kogerman P; Toftgard R; Huber M
J Exp Med; 2003 Dec; 198(12):1959-64. PubMed ID: 14676304
[TBL] [Abstract][Full Text] [Related]
39. Reciprocal activation between STAT3 and miR-181b regulates the proliferation of esophageal cancer stem-like cells via the CYLD pathway.
Xu DD; Zhou PJ; Wang Y; Zhang L; Fu WY; Ruan BB; Xu HP; Hu CZ; Tian L; Qin JH; Wang S; Wang X; Li YC; Liu QY; Ren Z; Zhang R; Wang YF
Mol Cancer; 2016 May; 15(1):40. PubMed ID: 27189061
[TBL] [Abstract][Full Text] [Related]
40. CYLD in ubiquitin signaling and tumor pathogenesis.
Ikeda F; Dikic I
Cell; 2006 May; 125(4):643-5. PubMed ID: 16713556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
